Additionally, considering the association between CIN levels and the response to taxane-based chemotherapeutic drugs [20, 21], the identification of carriers of deleterious BUB1B variants may also have significant implications for treatment decision-making. Here, BUB1B is linked to cervical squamous intraepithelial neoplasia.